bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules | BIAF Stock NewsStockTitan·12 hours agoBIAF-17.81%BIAFW0.00%
bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q SummaryTradingView·Aug 7 at 03:51 PMBIAF-17.81%BIAFW0.00%
BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 8-K: FY2026 Q2 Revenue: USD 1.511 MEarnings Watch·Aug 7 at 07:32 AMBIAFW0.00%
bioAffinity Q2 FY26 net loss narrows to $3.4 million; revenue rises 19% to $1.5 millionPUBT·Aug 7 at 07:02 AMBIAFW0.00%BIAF-17.81%
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung | BIAF Stock NewsStockTitan·Aug 6 at 11:00 PMBIAFW0.00%BIAF-17.81%
bioAffinity Technologies Faces Nasdaq Delisting Risk After NoticeTip Ranks·Jul 31 at 04:54 PMBIAFW0.00%BIAF-17.81%
bioAffinity Technologies faces Nasdaq delisting risk after shares trade below $1 bid-price minimumPUBT·Jul 31 at 04:15 PMBIAF-17.81%BIAFW0.00%
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung | BIAF Stock NewsStockTitan·Jul 26 at 11:08 PMBIAF-17.81%BIAFW0.00%
